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Oncogene-induced senescence (OIS) is a
barrier for tumor development. Oncogene-
dependent DNA damage and activation of
the ARF/p53 pathway play a central role in
OIS and, accordingly, ARF and p53 are
frequently mutated in human cancer. A
number of leukemia/lymphoma-initiating
oncogenes, however, inhibit ARF/p53 and
only infrequently select for ARF or p53
mutations, suggesting the involvement of
other tumor-suppressive pathways. We
report that NPM-ALK, the initiating onco-
gene of anaplastic large cell lymphomas
(ALCLs), induces DNA damage and irre-
versibly arrests the cell cycle of primary
fibroblasts and hematopoietic progeni-
tors. This effect is associated with inhibi-
tion of p53 and is caused by activation of
the p16INK4a/pRb tumor-suppressive
pathway. Analysis of NPM-ALK lymphom-
agenesis in transgenic mice showed
p16INK4a-dependent accumulation of se-
nescent cells in premalignant lesions and
decreased tumor latency in the absence
of p16INK4a. Accordingly, human ALCLs
showed no expression of either p16INK4a
or pRb. Up-regulation of the histone-
demethylase Jmjd3 and de-methylation
at the p16INK4a promoter contributed to
the effect of NPM-ALK on p16INK4a, which
was transcriptionally regulated. These
data demonstrate that p16INK4a/pRb
may function as an alternative pathway
of oncogene-induced senescence, and
suggest that the reactivation of p16INK4a
expression might be a novel strategy to
restore the senescence program in some
tumors. (Blood. 2011;117(24):6617-6626)
Introduction
Oncogene-induced senescence (OIS) is considered a powerful
barrier to the clonal expansion of primary cells carrying mutated
oncogenes (like Ras) and a potent tumor-suppressive mechanism in
vivo.1 Expression of activated oncogenes in primary cells in vitro
leads to accumulation of DNA damage and up-regulation of both
ARF (alternative reading frame), which stabilizes p53, and
p16INK4a, which maintains pRb (retinoblastoma protein) in its
active, hypophosphorylated form.1 Notably, high levels of DNA
damage, p53, and hypophosphorylated pRb have been documented
in various premalignant lesions.2
ARF/p53 and p16INK4a/pRb are the most frequently mutated
tumor-suppressive pathways in human tumors. The contribution of
each to OIS, however, remains unclear. In primary mouse embryo
fibroblasts (MEFs), which have been widely used to model OIS in
vitro, its execution depends on ARF and p53 expression,3,4 whereas
expression of p16INK4a or pRb is dispensable.5,6 This suggests
that OIS is a DNA damage response mediated by activation of the
ARF/p53-pathway.7
Although p53 is the most frequently mutated gene in cancer,
 50% of human cancers do not carry mutations of p53. It is
thought that, in this situation, the mutation of other components of
the p53 pathway might lead to its functional inactivation. Surpris-
ingly, however, a number of oncogenic proteins lead to functional
attenuation of p53 or ARF: PML-RAR in acute promyelocytic
leukemias (APL),8 B-cell receptor-ABL in chronic myelogenous
leukemias (CML),9 NPM-ALK in anaplastic large cell lymphomas
(ALCLs)10 and cytoplasmic NPM in acute myeloid leukemias
(AMLs).11 Overall, clinical and experimental evidence suggests
that these oncogenes represent the initiating event of tumorigen-
esis, linking the initial steps of cancer development to their ability
to inactivate the ARF/p53 tumor-suppressive pathway. However,
considering the relatively low frequency of these tumors in the
human population, it is likely that they activate other, p53/ARF-
independent, tumor-suppressive pathways.
We investigated the effects of the expression of the oncogene
NPM-ALK in primary cells. NPM-ALK, composed of the N-
terminal portion of nucleophosmin (NPM) and the intracellular
domain of anaplastic lymphoma kinase (ALK), is found in  80%
of ALCLs. Fusion with NPM activates ALK tyrosine-kinase,
leading to the constitutive activation of different downstream-
pathways, including Ras/ Raf/MEK/ERK, PI3K/AKT, and JAK/
STAT12-.13 Transgenic expression of NPM-ALK in mice is suffi-
cient to initiate lymphomagenesis in the thymus.14 Mutations of
p53 are quite rare in NPML-ALK–expressing ALCL ( 5%-
10%).15 We report here the role of the p16INK4a/pRb tumor-
suppressor pathway in inhibiting NPM-ALK–dependent tumor
progression.
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Methods
Cell culture, transfection, infection, and RNA interference
Primary MEFs, U2OS, and packaging cell lines (Phoenix for retroviral
vectors and 239T for lentiviral vectors) were grown at 37°C in 20% O2 and
5% CO2, using DMEM supplemented with 10% fetal bovine serum. ALCL
cell lines (Karpas 299, TS, SU-DHL-1, and JB-6 provided by R.C.;
SUP-M2 and DEL provided by S.D.T.) were grown in RPMI plus 10%
serum. Fresh hematopoietic lin cells were purified from the bone marrow
of 8- to 12-week mice according to established procedures16 and grown in
RPMI plus 10% serum and cytokines (IL3, IL6, SCF; StemCell Technolo-
gies). Transfection was performed with a standard calcium phosphate protocol
for Phoenix and 293T cells and with Fugene (Promega) for U2OS cells.
For viral infection, MSCV-based retroviral vectors, expressing GFP
together with NPM-ALK, NPM-ALK K210R, mutated H-RasV12, or
p16INK4a, were packaged using Phoenix cells and then used to infect
primary low-passage MEFs, lin cells, or ALCL cell lines. As a control, an
empty MSCV retroviral vector only expressing GFP was used. Successfully
infected GFP-positive cells were selected by FACS sorting. MEFs and
ALCL cell lines were seeded at low density and counted daily. For colony
assays, 5000 lin cells were plated in methylcellulose (MethoCult GF
M3434, StemCell Technologies) and colonies were counted after 10 days.
For serial replating assays, colonies were collected and disaggregated after
counting and the same number of lin cells was plated again.16
For the JunB interference experiments, we used a lentivirus-based
vector (PsiCo17) expressing the GCATCAAAGTGGAGCGAAA sequence.
For NPM-ALK and STAT3 interference in ALCL cell lines (DHL and TS,
respectively), we used previously established cells with a doxocyclin-
dependent shRNA inducible system.18 Briefly, cells were treated with
doxocyclin 1 g/mL up to 96 hours. At 72 and 96 hours, protein and RNA
extracts were prepared and analyzed for p16INK4a levels both by Western
blot and Q-PCR (see “qChIP and quantitative PCR analysis” below for
details).
Mice
Experiments involving mice were performed according to national guide-
lines and after approval by the Institutional Review Board of the European
Institute of Oncology. ALK transgenic animals14 were bred with p16INK4a
KO mice19 and Arf KO mice4; all the experiments were conducted with
littermate controls.
Thymocyte cell-suspensions were obtained after mechanical disaggrega-
tion, filtration (40 m cell-strainer), red cell lysis, and PBS washings from
the thymi of approximately 6-week-old mice. Cells were permeabilized,
stained with an anti Ki67 antibody, and analyzed by FACS.
Immunoblotting and immunofluorescence
Immunoblotting (WB) and immunofluorescence (IF) experiments were
performed as described previously.20 All protein lysates for WB were
performed in Laemmli buffer. WBs were performed using the following
primary antibodies: polyclonal anti-p53 (FL-393, Santa Cruz Biotechnol-
ogy), polyclonal anti–mouse p16INK4a (M156), antitubulin (all Santa Cruz
Biotechnology), anti-H2AX (#613402; Biolegend), polyclonal anti-ARF
(Abcam), anti-Jmjd3 antibody (kindly provided by Gioacchino Natoli,
European Institute of Oncology, Milan, Italy), polyclonal anti–human
p16INK4a (sc368; Santa Cruz Biotechnology), anti–human Rb (554136;
BD Biosciences Pharmingen), antiphosphoRb (ser 807/11) (#9308; Cell
Signaling Technology), anti-STAT3 (#919; Cell Signaling Technology),
anti H-RAS (sc29; Santa Cruz Biotechnology).
For IF analysis, cells were seeded on coverslips and 24 hours later fixed
in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and
stained with primary mouse anti-H2AX antibody (Biolegend) and then
with a secondary anti–mouse CY3 fluorochrome-conjugated antibody.
Images were acquired at room temperature using a Hamamatsu C4742-95
camera on an Olympus Version 1.0 BX61 microscope. The acquisition
software was Cell^F (Olympus).
For the BrdU assay, cells were seeded on coverslips, treated with 33M
BrdU for 15, fixed with 4% paraformaldehyde, and analyzed by immuno-
fluorescence using an anti-BrdU antibody (BD Biosciences).
Senescence-associated -galactosidase assays were measured in MEFs
as described21 and in frozen sections of thymuses using the Senescence-
associated -galactosidase staining kit (Cell Signaling Technology).
qChIP and quantitative PCR analysis
For qChIP analyses, MEFs were grown and processed as described22 using
antibodies against H3K273me (Millipore). The p16INK4a promoter was
analyzed in the immunoprecipitated DNA using the primers listed in
supplemental Table 1 (available on the Blood Web site; see the Supplemen-
tal Materials link at the top of the online article). Immunoprecipitated DNA
from 1  106 cell equivalents was resuspended in 300 L of 10mM Tris at
pH 8.0. Real-time PCR was performed with 6 L of DNA per reaction and
200nM concentration of primers, diluted in a final volume of 20 L of
SYBR Green reaction mix (Applied Biosystems). Data represent the mean
of 3 measurements 	 SEM.
RNA for expression analysis was extracted using the RNAeasy MiniKit
(QIAGEN), treated with DNAse before elution from the column, and
retro-transcribed into cDNA for subsequent analysis by quantitative PCR
(qPCR). Each PCR contained 10 ng of cDNA template and primers at a
concentration of 800nM in a final volume of 20L of SYBR Green reaction
mix. Data represent the mean of 3 measurements 	 SEM. Primers are listed
in supplemental Table 1.
Luciferase assay
U2OS cells and MEFs were transfected with pCDNA3-based vectors
expressing NPM-ALK, NPM-ALK K210R, or mutated H-Ras, together
with a luciferase-based synthetic reporter for p53 activity20 and a cytomeg-
alovirus-LacZ vector as transfection control. Control U2OS cells and MEFs
were transfected with a pCDNA3 vector together with the same luciferase-
based synthetic reporter for p53 activity20 and cytomegalovirus-LacZ
vector. Luciferase activity was measured with a luminometer, using a
commercial luciferin solution (Promega) as a substrate. Results were
normalized for transfection efficiency by measuring the -galactosidase
activity.
DNA extraction, bisulfite treatment, and methylation-specific
PCR (MSP)
Genomic DNA was isolated from formalin-fixed paraffin-embedded samples,
using a commercial kit (QIAamp DNA FFPE Tissue kit, QIAGEN)
according to the manufacturer’s instructions. In each case, the percentage of
neoplastic cells was assessed in hematoxylin and eosin–stained slides
obtained from the same blocks before DNA isolation: the mean percentage
was 70% (range 50%-80%). Sodium bisulfite modification was performed
using EZ DNA Methylation Kit (Zymo Research). PCR primers distinguish-
ing between methylated and unmethylated p16 were used23 (supplemental
Table 1). Each run of amplification included (i) commercially available
CpG dinucleotide-completely methylated DNA (CpGenome Universal
Methylated DNA; Chemicon-Millipore) as a positive control; (ii) 2 different
negative controls, either CpG dinucleotide completely unmethylated DNA
(CpGenome Universal Unmethylated DNA; Chemicon-Millipore), or DNA
untreated by sodium bisulfite. The PCR products underwent electrophoresis
on 2% agarose gel and were then visualized under ultraviolet illumination
using ethidium bromide staining. Two methylation-specific PCR (MSP)
experiments for each sample were performed.
Tp53 gene sequencing
Genomic DNA was isolated from formalin-fixed paraffin-embedded samples
and used for PCR amplification. We designed primers (listed in supplemen-
tal Table 1) to amplify the tp53 gene from exon 5 to exon 8 under the same
PCR condition: 40 cycles, 94 degrees for 30 seconds, 60 degrees for
45 seconds, 72 degrees for 45 seconds. The PCR fragments were run on a
2% agarose gel, then quantified and purified with EXO-SAP enzymes (Life
Sciences). The purified amplicons were sequenced by using a BD 3.1 cycle
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sequencing kit (Applied Biosystems) and a 3730xl Sequencer, in standard
conditions. The results were analyzed using Mutation Surveyor 4.0 software.
Immunohistochemical analysis
The use of patient samples was approved by our Institutional Review
Board; all patients gave informed consent according to the Declaration of
Helsinki. Immunostaining for pRb, p16INK4a, and p53 was performed on
3-m-thick formalin-fixed, paraffin-embedded sections after heat-induced
antigen retrieval using polyclonal antisera (pRb, Santa Cruz Biotechnol-
ogy) or the monoclonal anti-p53 antibody DO7 (Dako) and anti-p16INK4a
(E6H4; CINtec). At least 500 neoplastic cells at 400 magnification were
analyzed by a qualified hematopathologist (Dr Pruneri, Division of
Pathology, European Institute of Oncology, Milan, Italy). Control sections
for antibody specificity included (i) sections from known positive control
tissues (for pRb: colon cancer; for p53: breast cancer bearing a p53
missense mutation leading to an intense nuclear immunoreactivity in more
than 90% of the neoplastic cells; for p16INK4a: squamous cell carcinoma
of the cervix); (ii) serial sections of the cases tested stained with an
unrelated isotypic mouse monoclonal antibody (for p16INK4a and p53) and
normal rabbit serum (for pRb), as negative controls.
Statistics
Statistical analysis was performed using JMP Version 6.0 software.
Statistical significance was evaluated by nonparametric Mann-Whitney U
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Figure 1. NPM-ALK inhibits p53 activity and it induces a senescent checkpoint in primary fibroblasts. (A-F) WT MEFs were infected with control (Ctrl) and NPM-ALK
(NA) or RASV12 expressing retroviruses. (A) Cells were analyzed (5 days after infection) by immunofluorescence (magnification 600) and Western blot (B) with an
anti-H2AX antibody (representative micrographs and percentage of labeled cells are shown). (C) Growth curve of infected cells plated after infection and counted daily (cell
numbers are expressed relative to day 1; *P 
 .05 relative to control cells infected with an empty vector). (D) -galactosidase detection (representative micrographs
[magnification 600] and percentage of positive cells) and anti-BrdU staining (percentage of positive cells relative to control cells) performed 6 and 4 days after infection,
respectively. (E) Western blotting of p53, ARF, p16INK4a, NPM-ALK, and tubulin expression, 4 days after infection. (F) Western blotting of pRb, NPM-ALK, cyclin A, and tubulin
expression, 3 days after infection. (G) Luciferase assay in WT MEFs transduced with the pGL13 p53-reporter, the CMV-Gal vector, and increasing amounts of vectors
expressing NPM-ALK or the K210R kinase-dead NPM-ALK mutant (or a control empty vector). Data are from 3 independent experiments and normalized to Gal. *P 
 .05
relative to control cells infected with an empty vector. (H) Same Luciferase assay as in panel G comparing a single dose (100 ng) of NPM-ALK– and RASV12-expressing
vectors.
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test (Wilcoxon-Kruskal Wallis). Mouse survival was analyzed using the
Kaplan-Meier survival curve.
Results
Early-passage wild-type (WT) MEFs were infected with retrovi-
ruses coding for the green fluorescence protein (GFP) and either
NPM-ALK (NA vector) or oncogenic RAS (Valine-12 mutation;
RasV12 vector) proteins. Cells were infected for 2 days, replated,
and analyzed at different time points. Activation of a DNA-damage
response was assessed by immunostaining and Western blotting of
phosphorylated H2AX (H2AX). Like RasV12, the expression of
NPM-ALK caused accumulation of H2AX in the cells (Figure
1A-B). Analysis of the effects of NPM-ALK or RasV12 on cell
proliferation showed inhibition of fibroblast growth with both
oncogenes (Figure 1C). Notably, NPM-ALK and RasV12-
expressing cells became large and flat, acquired positivity for the
SA--galactosidase senescence-associated marker ( 20% and
 50% of cells, respectively), and showed reduction of bromode-
oxyuridine (BrdU) incorporation (Figure 1D). The growth-
inhibitory effect of NPM-ALK was dependent on an intact kinase
domain (supplemental Figure 1). Together, these findings suggest
that the expression of the NPM-ALK kinase in primary fibroblasts,
like that of oncogenic Ras, induces DNA damage and cellular
senescence.
To investigate the molecular basis of NPM-ALK–induced
senescence, we analyzed the protein levels of p53, ARF, and
p16INK4a by Western blotting. As expected, RasV12 induced
marked up-regulation of p16INK4a, ARF, and p53 (Figure 1E).
Accordingly, it activated reporter gene transcription from a syn-
thetic p53-dependent promoter in the same cells (Figure 1H). Like
RasV12, NPM-ALK induced p16INK4a expression, whereas it
only modestly increased levels of p53 and ARF (Figure 1E) and
reduced p53-dependent transcription in our experimental system
(Figure 1G-H). Again, the activity relied on an intact kinase domain
(Figure 1G). Thus, at variance with RasV12, which activates both
p53 and p16INK4a, NPM-ALK activates p16INK4a and, as
previously reported, inhibits p53 transcriptional activity.10
P16INK4a inhibits the activity of cyclin dependent kinases (CDKs)
that in turn phosphorylate pRb, blocking its activity. Therefore, we
evaluated levels of pRb phosphorylation. As shown in Figure 1F,
NPM-ALK– and RasV12-infected MEFs showed reduced levels of
pRb phosphorylation (which correlates with the observed cell-
cycle arrest and low S-phase specific cyclin A), thus confirming
increased p16INK4a activity in these cells.
To investigate whether activation of the p16INK4a/Rb pathway
is functionally required for NPM-ALK–induced senescence of
fibroblasts, NPM-ALK (or RasV12) was expressed in MEFs
derived from p16INK4a- or Rb1-null mice. RasV12 expression
inhibited proliferation in both cell types, confirming that this effect
is p16INK4a/pRb-independent, as already reported.5,6 Conversely,
NPM-ALK failed to induce a proliferative block in either p16INK4a-
or Rb1-null MEFs (Figure 2A-B), suggesting that NPM-ALK–
p16INK4a-/- MEFs
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Figure 2. NPM-ALK induced senescence requires an
intact p16INK4a/pRb pathway. Growth curves of
(A) p16INK4a/ or (B) Rb1/ MEFs infected with the
indicated retroviruses. Values are expressed relative to
day 1. In each panel, results are representative of at least
3 independent experiments. *P values are relative to
control cells infected with empty vectors. (C) Methylcellu-
lose-CFU of WT or p16INK4a/ lin cells infected with
the indicated retroviruses (graph and representative im-
ages). Values are expressed relative to control infected
cells. (D) Serial replating of WT and p16INK4a/ lin
cells infected with the indicated retroviruses. CFUs are
expressed relative to the first count for each sample.
Results are representative of 3 experiments. *P 
 .05
relative to control cells infected with an empty vector.
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induced senescence of primary fibroblasts is, instead,
p16INK4a/pRb-dependent.
To confirm these findings into another type of primary cells,
NPM-ALK was expressed into a bone marrow subpopulation
enriched in stem cells and progenitors (lineage negative [lin]
cells). These cells likely contain putative lymphoma-initiating
cells, as shown by the findings that transplantation of NPM-ALK–
transduced bone marrow24 or lin (data not shown) cells results in
lymphoma development in the recipient mice. Expression of
NPM-ALK in lin cells induced a marked reduction in their
proliferation properties, which was completely rescued by the loss
of p16INK4a (as assessed by the methyl-cellulose colony-
formation assay; Figure 2C). Notably, the colonies obtained from
p16INK4a-null lin cells expressing NPM-ALK were markedly
larger (Figure 2C). Control primary colonies from WT and
p16INK4a-null lin cells exhausted their proliferative potential
after the third replating in methylcellulose (Figure 2D). Strikingly,
the number of NPM-ALK–expressing p16INK4a-null colonies, but
not of the NPM-ALK–expressing WT colonies, expanded geometri-
cally at each replating (Figure 2D). Together, these observations
demonstrate that loss of p16INK4a prevents the proliferative arrest
induced by NPM-ALK in hematopoietic progenitors and unmasks
its oncogenic potential, as shown by the increased clonogenic
activity (numbers of primary colonies), proliferative activity (colony
size), and replication potential (serial replating).
Finally, to assess the in vivo role of p16INK4a in an NPM-ALK–
mediated lymphomagenesis model, we used mice expressing the
NPM-ALK transgene under the control of the lymphoid-specific
CD4 promoter; these mice develop thymic lymphomas with a mean
survival of 18 weeks.14 Thymi from NPM-ALK transgenic mice
(collected before the occurrence of histopathologic signs of lym-
phoma) showed a significantly higher frequency of SA--
galactosidase–positive cells ( 10%-15% vs 0.5%-1.5%; Figure
3A), and a reduction in Ki67-positive cells (Figure 3B), compared
with matched control littermates. Strikingly, thymi from NPM-
ALK–p16INK4a-null intercrosses showed frequencies of senes-
cence-like cells comparable to that of WT or p16INK4a-null mice
(Figure 3A), suggesting that NPM-ALK–induced senescence in
vivo also depends on p16INK4a expression.
To examine in vivo the effect of the p16INK4a/pRb pathway in
limiting tumor progression, we monitored NPM-ALK tumorigen-
esis in a p16INK4a-null or p16INK4a-heterozygous (p16INK4a-
het) background. All the analyzed NPM-ALK transgenic mice,
regardless of their p16INK4a genotype, died as a consequence of
thymic lymphomas (with large or medium-sized cells; not shown).
Tumor latency in the transgenic mice expressing NPM-ALK in a
p16INK4a-WT context was as reported.14 Loss of either one or both
p16INK4a alleles resulted in a significant reduction in tumor
latency, with a mean time-to-death of 103 and 113 days in the
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p16INK4a-het and p16INK4a-null backgrounds, respectively, com-
pared with 139 days in the WT background (Figure 3C). The
observation that tumor latency was similarly reduced in the
p16INK4a-het and p16INK4a-null mice suggests the existence of a
strong pressure to lose or inactivate p16INK4a during ALCL
tumorigenesis. Indeed, we did not observe any detectable p16INK4a
expression in 7 of 8 lymphomas obtained from p16INK4a-het mice,
nor in 3 of 4 tumors from WT mice (Figure 3D). Notably, the same
samples showed expression of p53 and ARF (Figure 3D). These
data indicate that NPM-ALK–driven tumorigenesis in mice is
physiologically constrained by the activation of the p16INK4a
tumor-suppressor program, and that its inactivation is necessary for
ALCL to develop.
Having shown, both in vitro and in vivo, that the expression of
NPM-ALK elicits a senescence response, that in turn limits cell
proliferation in vitro and tumor progression in vivo, the next step
was to verify whether loss of p16INK4a and/or pRb expression is a
necessary requisite for tumor development. We performed this
analysis in human NPM-ALK–expressing ALCL samples, using
primary patient samples and established cell lines. Expression of
p16INK4a and pRb in primary ALCLs was evaluated by immuno-
histochemistry in 19 samples (Table 1 and supplemental Figure 2
for representative results). Notably, 17 showed no expression of
either the p16INK4a or pRb protein, 1 sample very low expression
of both proteins, and 1 sample a high percentage of tumor cells
expressing both p16INK4a and pRb. The p16INK4a promoter was
hypermethylated in 3 of 11 cases analyzed (see supplemental
Figure 3 for representative results). Of these 3 cases, 2 displayed no
p16INK4a expression and 1 very few (5%) p16INK4a-expressing
cells. Several samples (10/19) showed a medium to high percent-
age of p53 positive tumor cells (between 11% and 70%), the
remaining samples displayed low positivity (between 2% and 10%;
Table 1). We also performed mutational analysis of the Tp53 gene.
Successful DNA amplification of exons 5 to 8 was obtained in
13 cases, all of them showing a WT sequence.
We then evaluated the expression of p16INKa and pRb in
6 ALCL cell lines by Western blot analysis. Three showed no
expression of p16INK4a (Figure 4A) and hypermethylation of its
promoter (see supplemental Figure 3 for representative results). All
6 cell lines showed pRb expression (Figure 4A). Notably, and
regardless of the expression of p16INK4a, all of them showed high
levels of the phosphorylated form of pRb, which corresponds to its
inactive state (Figure 4A). Thus, other mechanisms may have been
selected in the p16INKa-expressing ALCL cell lines to inactivate
pRb. Together, these data suggest that inactivation of either
p16INK4a or pRb is a near-constant feature of human NPM-ALK–
expressing ALCLs. Their relative frequency, however, was signifi-
cantly different in primary samples versus cell lines. In particular,
pRb-positive ALCL cases were very frequent in the ALCL cell
lines, suggesting that expression of hyperphosphorylated pRb
might be critical for growth in culture and establishment of a cell
line. This observation correlates with the fact that the pRb-positive
ALCLs express hyperphosphorylated pRb, are more aggressive,
and are associated with a worse prognosis.25
We then investigated the mechanistic relations among NPM-
ALK expression, p16INK4a expression, and cellular growth in the
ALCLs. To test whether NPM-ALK expression is required to
maintain high levels of p16INK4a expression, we silenced NPM-
ALK by RNA interference in the p16INK4a-expressing SU-DHL-1
ALCL cell line. As shown in Figure 4B, silencing of NPM-ALK
resulted in decreased levels of p16INK4a mRNA and protein. To
test whether loss of p16INK4a expression is critical for tumor
growth in the p16INK4a-negative ALCLs, we re-expressed
p16INK4a in the Karpas299 and DEL ALCL cell lines. Re-
expression of p16INK4a in these cells impaired cell-cycle progres-
sion and, accordingly, reduced levels of phosphorylated pRb
(Figure 4C). Notably, the same effect was obtained by treating the
cells with the de-methylating agent 5-azacytidine, which induced
the re-expression of p16INK4a (Figure 4D).
Table 1. Expression of p16INK4a, p53, and pRb in 19 tumor specimens from ALCL ALK patients by immunohistochemical analysis with
specific antibodies
Negative samples are highlighted in green. Numbers represent the percentage of positive tumor cells in each sample. Analyses of Tp53 gene sequence (p53seq) and
p16INK4a promoter methylation state (p16-promoter) are also included.
samples 
1 0 0 4 UNMET WT 
2 5 0 20 MET nt 
3 6 0 20 UNMET WT 
4 0 0 15 MET WT 
5 0 0 25 UNMET WT 
6 7 0 9 nt nt 
7 0 0 3 nt WT 
8 50 0 2 UNMET WT 
9 5 0 30 UNMET WT 
10 3 2 20 nt WT 
11 0 0 15 nt WT 
12 45 30 70 nt WT 
13 0 0 2 UNMET WT 
14 0 20 7 MET WT 
15 60 0 5 UNMET nt 
16 10 0 3 nt nt 
17 0 0 12 nt nt 
18 3 0 4 UNMET WT 
19 0 0 17 nt nt 
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Finally, we investigated the molecular mechanisms underlying
the effect of NPM-ALK on p16INK4a expression. p16INK4a
transcription is repressed by polycomb-containing complexes,
which induce tri-methylation of lysine 27 of histone H3 (H3K273me)
at the p16INK4a proximal promoter. Removal of H3K273me is
critical for p16INK4a transcriptional up-regulation during replica-
tive senescence.26 We first investigated whether up-regulation of
p16INK4a by NPM-ALK is associated with H3K27 de-methyl-
ation and increased p16INK4a transcription, using chromatin
immunoprecipitation (ChIP) and qPCR, respectively. NPM-ALK
induced a marked decrease of H3K273me, which was detectable
1 day after expression, and was more pronounced at days 3 and 5
(Figure 5A). Levels of p16INK4a transcripts also increased follow-
ing NPM-ALK expression, with a slightly delayed kinetics (Figure
5A), suggesting that the effect of the fusion-protein on p16INK4a is
transcriptional and involves de-methylation of H3K27.
We then examined NPM-ALK–dependent signaling pathways
involved in p16INK4a transcriptional de-repression. The transcrip-
tion factor JunB is overexpressed in human ALCLs and induces
p16INK4a-dependent senescence in MEFs.27 Expression of NPM-
ALK in MEFs induced up-regulation of JunB (Figure 5C).
However, NPM-ALK also induced p16INK4a up-regulation and
proliferative arrest in MEFs in which JunB was silenced by short
interfering RNA (shRNA), indicating that JunB is not involved in
this process (Figure 5B-C). It has been recently shown that the
histone de-methylase Jmjd3 actively de-methylates the p16INK4a
promoter during oncogene- and stress-induced senescence, thus
favoring p16INK4a transcriptional activation.28 In MEFs, NPM-
ALK induced up-regulation of both Jmjd3 and p16INK4a (Figure
5D). Strikingly, NPM-ALK did not induce a proliferative arrest of
Jmjd3-null MEFs, although cell growth of NPM-ALK–expressing
Jmjd3-null MEFs was consistently lower than control Jmjd3-null
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cells (Figure 5E). Accordingly, the NPM-ALK–induced p16INK4a
up-regulation in Jmjd3-null MEFs was reduced, but not prevented
(Figure 5F), suggesting that Jmjd3 only partially contributes to
activation of p16INK4a by NPM-ALK. To investigate other
pathways, we analyzed STAT3, a key transcription factor in the
NPM-ALK signaling pathway.29 Down-regulation of STAT3 expres-
sion in the TS ALCL cell line by RNA interference, led to reduced
levels of p16INK4a both at protein and mRNA level (Figure 5G).
Thus, multiple signaling pathways, including Jmjd3 and STAT3,
contribute to the activation of the p16INK4a tumor-suppressive
pathway by NPM-ALK.
Discussion
Our data provide genetic evidence that the p16INK4a/pRb pathway
is involved in the execution of OIS, both in vitro and in vivo, and
strongly suggest that it represents an alternative barrier to tumor
development when tumorigenesis is initiated by oncogene muta-
tions that inhibit the ARF/p53 signaling pathway. This conclusion
is based on the finding that NPM-ALK limits p53 transcriptional
activity when expressed in primary cells, yet it induces senescence
by activating the p16INK4a/pRb pathway, both in cultured cells
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and in vivo. This hypothesis is also supported by the observations
that NPM-ALK lymphomagenesis is accelerated in mice lacking
p16INK4a expression, and that p16INK4a and/or pRb expression
is frequently lost in primary ALCLs, whereas p53 is variably
expressed (10 of 19 cases with  10% p53-positive tumor cells;
Table 1), but never mutated (13 of 13 cases). The p16INK4a/pRb
pathway might have a similar function in other tumor types
characterized by infrequent mutations of p53 and an overt ARF/p53
inhibitory effect of the corresponding initiating oncogene. This is
the case for AMLs, including those expressing PML-RAR,
cytoplasmic NPM, or B-cell receptor ABL. The list might be
longer, considering that other AML-associated fusion proteins,
such as TEL-JAK2, TEL-PDGFR, and TEL-TRKC, inactivate p53
and induce p16INK4a and cell-cycle arrest on expression in MEFs
(our unpublished results).
The finding that NPM-ALK or other leukemia oncogenes
antagonize the ARF/p53 pathway argues against its involvement as
a tumor-suppressive mechanism for these oncogenes. Indeed,
NPM-ALK markedly reduced the clonogenic activity and replica-
tion potential of Arf-null lin cells, and induced lymphomas with
the expected latency and incidence when expressed into Arf-null
mice (supplemental Figure 4A-B). However, expression of NPM/
ALK in Arf-null MEFs did not induce expression of SA--
galactosidase (not shown) and only provoked a transient cell-cycle
arrest, as, after 6-8 days, the cells re-entered the cell cycle
(supplemental Figure 4C-D), suggesting that expression of ARF is
required for the pro-senescence effect of NPM-ALK in MEFs.
Even though MEFs do not represent the physiologic cell of origin
of ALCLs, these findings suggest that in specific cell types and/or
physiologic settings, the integrity of the ARF/p53 pathway might
be necessary for the tumor-suppressive function of p16INK4a/Rb.
Interestingly, p53 mutations are occasionally observed in ALCLs
and other hematopoietic tumors (including APLs and AMLs).
Our data have implications for the treatment of ALCLs and
other hematopoietic tumors carrying a WT ARF/p53 pathway.
Re-expression of p53 in tumors with mutated Tp53 activates the
senescence or apoptotic program and induces tumor regression.30
Under these circumstances, the exogenously expressed p53 be-
comes transcriptionally competent, because of the persistence of
the mutated oncogene that ensures chronic activation of upstream
components of the ARF/p53 pathway. The same effect can also be
achieved with drugs that target p53 in tumors carrying WT Tp53
alleles and attenuated p53 signaling, because of genetic alterations
of other components of the ARF/p53 pathway.31 In principle, this
effect cannot be achieved in ALCLs or other hematopoietic tumors,
where the ARF/p53 pathway, although unmutated, is functionally
suppressed by NPM/ALK or other initiating oncogenes. Restora-
tion of oncogene-induced senescence, in these tumors, might
instead be achieved by reactivation of p16INK4a/pRb. Notably, our
finding that 5-azacytidine-treatment of ALCL cells, in which
p16INK4a is inactivated by promoter hypermethylation, resulted in
cell-cycle arrest, strongly suggests that specific de-methylating
agents might find a role in the treatment of a subset of ALCLs.
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